IFPA
GLOBAL LEADER IN FIGHTING
PSORIATIC DISEASE



IFPA org no 802428-5986

Annual Accounts 2025

Content

Director's Declaration 2025

IFPA, the International Federation of Psoriasis Associations, founded in 1971, and based in Stockholm, Sweden, is the global organization dedicated to advocating for everyone living with and affected by psoriatic disease. IFPA's members represent more than 100 million people worldwide.

Disease Prevalence

According to the Global Psoriasis Atlas, an estimated 43 million people have psoriasis based on reporting physician/dermatologist diagnoses. An estimated 102 million people have psoriasis based on self-report cases provided by individuals. The physician-diagnosed prevalence is based on data from 41 countries where studies are available.

These figures highlight an important reality: many people with psoriatic disease remain undiagnosed or are unable to access appropriate care. This suggests that the global burden of psoriatic disease is likely higher than what existing studies can fully capture. These insights underscore the importance of continued efforts to improve awareness, diagnosis, and access to treatment worldwide.

Purpose of the Federation

IFPA is the global voice dedicated to advancing psoriatic disease policy. IFPA is the trusted convener of psoriatic disease stakeholders across sectors and geographies, partnering to strengthen national and regional capacity and leadership. IFPA works with others to generate and share evidence to inform change that can address unmet needs for people living with psoriatic disease.

- **Legitimacy to represent people living with psoriatic disease:** IFPA is the only organization that brings a unified global voice of people living with psoriatic disease to the global agenda.
- **History and track record in the psoriatic disease community:** IFPA has been unifying the psoriatic disease community and has a proven track record of elevating psoriatic disease onto the global agenda.
- **Independence and integrity:** Decisions are exclusively driven by the needs of the people living with psoriatic disease.

Vision

A future where all people living with psoriatic disease enjoy good health and wellbeing, free from stigma and preventable disability and comorbidities.

Mission

Unite, strengthen and lead the global psoriatic disease community to improve the lives of all people affected by psoriatic disease.

Goals

Ensure global representation: Boost the voices of everyone living with psoriatic disease, everywhere.

Lead global advocacy: Fight for the interests of people affected by psoriatic disease. Demand representation on global health and development agendas.

Strengthen member capacity: Strengthen IFPA members. Raise national support for people living with psoriatic disease.

Share knowledge: Close the gap between knowledge and action. Trigger breakthroughs for people living with psoriatic disease.

Unite stakeholders: Build alliances. Transform global, regional, and national collaboration.

The interrelated goals are equally important and support each other. The strategic goals are further broken down in different activities with performance indicators set for 2030.

In addition to goals, four core values are identified, as well as a number of priority issues, those cross-cutting issues that influence the strategic goals and vary in relevance and importance. The priority issues identified by IFPA, and its stakeholders, very much reflect the recommendations set out in the WHO Global Report on Psoriasis in 2016.

Values

Person-centered: Ensure that people living with psoriatic disease are at the heart of everything IFPA does.

Collaborative: Work together and openly with members and partners.

Accountable: Be responsible for all actions

Bold: Have the confidence and courage to lead the global psoriatic disease community.

Priority issues

Equal access to treatment, specialists and individualized care: People living with psoriatic disease require access to appropriate treatment and care, including trained healthcare professionals and medicines. However, inadequate access to healthcare is a challenge in many countries across the world.

Early diagnosis of psoriatic disease: People living with psoriatic disease can experience unnecessary suffering, irreversible deformities of the joints and disability due to late diagnosis and lack of appropriate treatment. One standard global guideline to help promote early diagnosis of and appropriate treatment for people living with psoriatic disease.

Making healthcare providers aware of psoriatic disease: Lack of adequate training for healthcare practitioners and providers results in low awareness of psoriatic disease. Increased awareness and understanding of psoriatic disease among those responsible for providing care can help facilitate early diagnosis and appropriate treatment.

Stop stigma: People with psoriatic disease still experience stigmatization and discrimination. Public misconceptions about psoriasis, for example the myth that it is a contagious disease, result in people with psoriatic disease being excluded from everyday life and foster low self-esteem, depression and even suicidal thoughts.

Change the perception of psoriatic disease and call for consensus on categorizing severity: Psoriatic diseases are complex and unpredictable conditions with varied manifestations and associated diseases that affect individuals differently. The misperception that psoriatic disease is a mere skin condition and the lack of consensus on categorizing the severity levels of the condition can lead to inadequate treatment and care.

Multidisciplinary care: People living with psoriatic disease require access to multidisciplinary care to identify and manage common comorbidities that already exist or may develop, including cardiovascular and metabolic diseases (such as diabetes) and psychological conditions. Multidisciplinary care teams include primary care physicians, dermatologists, rheumatologists, psychologists, psychiatrists, pediatricians, cardiologists, and endocrinologists.

Link psoriatic disease and mental health: Psoriatic disease causes great physical, emotional, and social burdens, all of which may impair an individual’s quality of life and be psychologically devastating. Increased awareness and focus on the link between psoriatic disease and mental health can help improve quality of life and wellbeing for people living with psoriatic disease.

Join forces with family and community: Psoriatic disease affects relationships at home, school, and work, as well as intimate relationships. Community support, caretakers, and families should be included in the fight against psoriatic disease.

Year 2025

Theme of the year: Psoriatic Disease and Comorbidities

Psoriatic disease has a severe impact on the lives of those living with the disease. It is estimated that more than 100 million people worldwide live with psoriatic disease, and that there is an increased risk of developing other noncommunicable diseases (comorbidities).

In 2025, IFPA focused on the link between psoriatic disease and comorbidities, highlighting its complexity and impact on the whole body, mental health, and all aspects of life.

The year provided an important opportunity to spread the message through our global #StopTheDominoEffect campaign. We called for action to ensure psoriatic disease is recognized within the global noncommunicable disease (NCD) agenda. IFPA brought psoriatic disease to the global stage at the United Nations General Assembly and gathered policymakers in Geneva on World Psoriasis Day.

Thanks to the support and coordinated efforts by IFPA’s members, partners and other stakeholders across the community, a growing number of experts and decision-makers now recognize psoriatic disease as a serious, systemic condition that must be addressed in health policies. Their dedication and commitment have helped bring IFPA closer to our vision

– a world where people with psoriatic disease have access to care and support, enjoy a full life, free from stigma and discrimination.

Below follows a description of IFPA's activities and achievements during the year.

Governance

General Assembly

The General Assembly, consisting of IFPA's full Members, is the highest decision-making body of IFPA. The General Assembly meets every three years, and this year's meeting was held on April 6 in Bogota, Colombia.

The meeting was chaired by Christy Langan, CEO of International Psoriasis Council (IPC). The General Assembly approved the periodic reports for 2022, 2023 and 2024, together with the Auditor's report for the same years, and discharged the Board from responsibility for that period. The Board had proposed amendments to the IFPA Constitution which were accepted by the General Assembly. Finally, the General Assembly elected a new Board, composed of a President and six members, and decided to not adjust the membership fees.

Board Meetings

In 2025 the IFPA Board had ten (10) Board meetings, of which three (3) were physically conducted.

Secretariat

During 2025 the IFPA Secretariat consisted of the:

- Executive Director
- Finance & Administration Manager
- Accounting Administration Officer – new role
- Communications Lead
- Design & Social Media Communicator
- Community Manager
- Strategic Events & Project Lead
- Policy & Advocacy Manager
- Policy & Advocacy Lead – new role
- Scientific Officer
- Scientific Project Lead

The number of full-time staff positions at the Secretariat was 11 (9).

Members

This year two new member organizations were welcomed from Honduras and Rwanda. IFPA also witnessed the birth of a regional patient organization, PsorAfrica. By December 31, 2025, IFPA had 64 (60) national member organizations in 61 (57) countries and 3 regional member organizations.

IFPA Member Meeting 2025

The Member Meeting was held in connection with the IFPA Forum and General Assembly in Bogota, Colombia, on Sunday, April 6, and brought together 70 onsite patient advocates and psoriatic disease stakeholders from all over the world. The discussion and training centered on several topics including:

- Foundations of advocacy
- Collaboration between HCPs and patient organizations
- National treatment guidelines
- Reclassification of psoriasis severity
- Reaching rural areas
- Representation & diversity
- Funding for patient organizations
- Psoriatic disease and the environment
- NCD advocacy
- Member presentations
- World Psoriasis Day presentations

Member Survey

In IFPA's global strategy, 'Strengthen member capacity' is one of the five main goals. It is therefore important for IFPA to continually collect reports from our national and regional members around the world. These surveys help us understand the global impact of our organization on the lives of people living with psoriatic disease. They also influence our strategy for continued improvement of the organization.

The 2025 Member Reporting was conducted December 2025 - January 2026 and organized into three areas:

- Impact Report
- Feedback on 2025
- Input for 2026

43 (31) members reported. Member satisfaction is crucial to IFPA and by 2025 we set out to have a satisfaction rate of 4+ out of 5. The member satisfaction rate for 2025 was 4.2 (4.3).

In addition to the reporting, all members were offered individual calls with the IFPA Community Manager. 23 (24) calls were held.

More details from the member reporting will be available on the website during spring 2026.

Notable regional actions in 2025 include the formation of a new African regional organization called PsorAfrica, and a refreshed alignment of IFPA's European members in EUROPSO around their 2022 goals from the IFPA Forum in Milan.

Member Portal

The Member Portal is a platform with resources to meet the members' needs that is:

- A knowledge hub hosting the latest psoriatic disease research
- A collaborative space for communication between members

- A learning center to continue building capacity and skills
- A place to showcase national work
- A library of resources

The user-friendly community platform houses a calendar of IFPA events, a library of resources, access to virtual trainings, discussion forums, and virtual working groups for IFPA's different projects. Members have been steadily entering the platform, currently there are 99 people registered.

Community Corner

In 2025, IFPA held 9 Community Corner meetings. This series of virtual monthly meetings is open to IFPA members. Instead of the presenter/audience format of a normal webinar, Community Corner is a discussion space. Members share ideas around a specific topic, and IFPA invites interesting guests to facilitate the conversation. Topics from 2025 included:

- IFPA's Board and how the General Assembly works
- World Psoriasis Day theme development for 2025 - comorbidities
- Research and Members in Science
- Funding pullback and the new era of global health
- Wellness and psoriatic disease
- IFPA's Ambassador program
- UNGA and national advocacy
- Patient involvement in clinical trials
- World Psoriasis Day 2026 theme planning – Youth

IFPA Accelerator Program

The Accelerator program is one of our four flagship programs, a training program that supports organizations to expand their work and guides new advocates in establishing patient associations.

The program aims to:

- Accelerate the growth of IFPA
- Leverage the skills and capacities of selected member associations in each region
- Strengthen regional alliances and facilitate best practice sharing within regions

In 2025, a training was initiated to use AI tools to develop real-world data surveys, conduct the surveys, analyze the data, and create infographics to display the results.

IFPA Start-Up Program

The IFPA Start-Up Program is a part of the Accelerator Program and aims to expand IFPA's global network by empowering motivated individuals to become effective patient advocates and leaders. It supports those who wish to establish psoriatic disease organizations in countries where none currently exist.

Participants receive:

- Practical training on building and managing organizations
- Targeted financial support for first steps

Impact so far:

- 18 enrolled in the program
- 2 newly registered organizations (Gambia & Nigeria)
- 2 active in the process (Paraguay & India)
- 5 individuals received financial support with the purpose of establishing a patient organization

IFPA Funds

With different funds IFPA supports efforts worldwide to strengthen patient organization's ability to act. Read more on IFPA Project Funding page.

Dr. Hoseah Waweru Solidarity Fund

The IFPA Solidarity Fund was created to address the funding gap faced by many of IFPA's members, by awarding grants to support advocacy, education and awareness-raising in psoriatic disease. After the passing of IFPA's President in 2024, the Fund was renamed in his memory. This year the Fund had one call for application. 8 out of 15 applying organizations were elected to share 22,000 EUR (275,000 SEK).

IFPA Start-Up Fund

The IFPA Start-Up Fund was created in 2023 to support individuals or groups who reside in a country where there doesn't exist a patient association, and who has the ability to start one. For this reason, the Start-Up funding is connected to specific projects, Start-Up projects, with the purpose of starting new patient associations.

In 2025, Start-Up projects were initiated in Gambia and Paraguay.

Project Rare GPP

The Project Rare GPP fund is an opportunity for patient organizations to reach those in their region living with GPP (Generalized Pustular Psoriasis). National patient organizations are crucial to the fight against psoriatic disease and often lack resources to carry out all the projects they wish for. With the financial assistance from this fund, they can realize some of these projects.

During 2025, the Fund had two calls for application, where applying organizations could share a total of 100,000 EUR.

The first round was closed in March, 3 out of 10 project applications were elected.

The second round was closed in September, 4 out of 10 project applications were elected.

Communications

Communication channels

IFPA Update and Newsletters

IFPA continued its internal newsletter, the IFPA Update, to communicate more frequently with members, sending 57 newsletters throughout the year to keep members informed about developing projects and opportunities.

Additionally, IFPA distributed two newsletters to external recipients, including stakeholders, partners, and other key audiences. These newsletters highlighted important updates on the IFPA Forum in Bogota, IFPA's participation around the UN General Assembly, World Psoriasis Day, other initiatives in 2025 and various plans for 2026.

Website

Some of the analytic insights for 2025 (2024):

Organic page views 17,400 (17,721). The top five countries frequenting the IFPA website being the USA, UK, India, Sweden, and Jamaica. The most visited web pages include the Homepage, World Psoriasis Day, and its campaign materials page, IFPA Forum, and IFPA Conference, underlining the diverse interests of visitors, from general information to specific events and campaign details.

Social media

In 2025, IFPA focused on evaluating its content strategies for social media and looking for ways to improve them to engage the audiences across channels more effectively. At the same time, the Communications team continued to create and publish diverse content to drive awareness around IFPA's projects and activities, highlight member organizations' successes and build connections with the audiences and attract new followers.

Among the key content themes, visible in IFPA's social media channels in 2025, were:

- World Psoriasis Day 2025 with the key message #StopTheDominoEffect - a series of posts included over 60 diverse items
- Social media content, devoted to various International Observation Days, including World Cancer Day, Obesity Day and more
- Content, reporting about IFPA's events, like a side-event at United Nations General Assembly in New York in collaboration with Devex
- A targeted social media campaign to attract new Ambassadors in Africa (resulted in over 80 applications and 9 ambassadors recruited)
- The strategic evaluation of IFPA's content in social media will be continued in 2026.

Followers per platform	**2025**	**2024**
LinkedIn	2,540	1,942
Instagram	4,197	3,533
X (Twitter)	6,376	6,438
Facebook	14K	14K
YouTube	618	567
TikTok	881	895

World Psoriasis Day

#StopTheDominoEffect

Psoriatic disease is a lifelong, systemic disease that can trigger a domino effect of other comorbidities like diabetes, cardiovascular diseases, depression and more. The campaign called for holistic care to break this cycle and improve lives

250,000

Our social media posts generated over **250,000** views on social media and over **500** shares

50

Over **50** dedicated social media posts (LinkedIn, Facebook, Instagram, X)

World Psoriasis Day (WPD) is the annual day dedicated to people living with psoriatic disease. WPD is celebrated on October 29, with the overall aim of:

- Raising awareness about the severity of the disease and the everyday challenges faced by people living with psoriatic disease
- Spreading information about psoriatic disease, refuting common misconceptions and increasing knowledge among people living with the condition
- Improving access to treatment by targeting health ministers, governments and decision-makers
- Creating a united platform to empower people living with psoriatic disease

World Psoriasis Day provides a unique opportunity for IFPA to take action, drive advocacy, and demonstrate leadership among multiple stakeholder groups. IFPA uses World Psoriasis Day to mobilize enthusiasm for a shared theme and goal.

World Psoriasis Day 2025 focused on the theme "Psoriatic Disease and Comorbidities", under the hashtag #StopTheDominoEffect, highlighting that psoriatic disease can trigger a domino effect of other comorbidities like diabetes, cardiovascular diseases, depression and more. The World Psoriasis Day Impact Report 2025 will be released in Q1, 2026, offering further insights.

The press release “World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis” had 705K recorded views with a potential reach of 2B.

Advocacy and Policy

IFPA Coalition

By collaborating across borders, sectors and disease areas, IFPA uses the Coalition to generate support to implement the recommendations outlined in the Global Report on Psoriasis, developed by the World Health Organization in 2016. The Coalition convened four times in 2025: February (virtual), June (virtual), September (in person) and December (virtual). During these meetings, the main initiatives in advocacy were discussed, namely:

- Resources, initiatives and events around the theme of the year, psoriatic disease and its comorbidities
- The IFPA Forum Americas and Africa, the resources developed for it and its follow-up
- IFPA's activities and plans with the World Health Organization

Coalition members gave helpful input and contributions to discussions to further amplify IFPA's advocacy work. In 2025, the IFPA Coalition counted 16 members from civil society, industry, and medical professional organizations.

The year of NCDs

The Advocacy and Policy team contributed to the development and execution of the theme of the year (psoriatic disease and its comorbidities). In particular, IFPA organized an event at the sidelines of the United Nations General Assembly titled "Psoriatic disease and NCDs: putting lived experience at the heart of policy" to highlight the importance of including lived experiences of people living with an NCD such as psoriatic disease when developing health policies. The event was organized in collaboration with Devex in New York and attracted a diverse audience of civil society organizations, international organizations, and policymakers, both in-person and online.

Moreover, IFPA organized the yearly diplomatic lunch in Geneva, titled "Towards inclusive health policies: addressing the hidden costs of psoriatic disease" with representatives from Permanent Missions to the UN in Geneva and senior representatives from WHO. The lunch was centered on comorbidities, the economic burden of comorbidities in psoriatic disease, and legal wins achieved around the world thanks to the work of IFPA and its member organizations.

Relationship with international policy bodies

IFPA participated in meetings and side events on the margins of the 78th World Health Assembly in Geneva.

IFPA was very active in maintaining the relationship established with a medical officer, as well as with the leadership, in the WHO / Neglected Tropical Disease department. The collaboration aimed at creating a joint workplan for the years to come.

IFPA's network in advocacy

IFPA renewed its membership in the International Alliance of Patients' Organizations (IAPO), the Global Health Council and the NCD Alliance. IFPA is also a member of the Civil Society Engagement Mechanism for Universal Health Coverage (CSEM), CoNGO and Rare Diseases International.

During 2025, IFPA became a member of the newly established Global Remission Coalition. IFPA actively participated in an advocacy driven round table discussion organized by the coalition as a side event of the World Health Assembly in Geneva. Other participants around the table were senior policy makers from the WHO.

IFPA participated in the Rare Disease Campaign 2025, providing toolkits on rare diseases to members and sharing awareness through social media. In preparation for the 2025 World Health Assembly (WHA), IFPA was actively supporting the Rare Diseases International campaign for a Resolution on Rare Diseases, which was officially adopted by WHA on May 24, 2025.

IFPA continued its collaboration with the International Alliance of Dermatology Patient Organizations (IADPO/GlobalSkin) and is member of the IADPO-led World Skin Health Coalition. IFPA participated in the side-event organized by IADPO in support of the skin resolution adopted at the yearly World Health Assembly.

IFPA continued the collaboration with the International Psoriasis Council (IPC) and had regular meetings and a few activities together, like a joint program at the IFPA Forum Americas, in Bogota, Colombia, on April 5. IFPA also attended the IPC Think Tank meeting, in San Juan, Puerto Rico on London on December 5.

IFPA Forum

The IFPA Forum is a Flagship program of IFPA designed to put the needs of people living with psoriatic disease at the center of the policy discourse at the regional level.

IFPA's third Forum was held in Bogota, Colombia, on April 4, 2025. Ahead of the Forum, several resources (Briefing book and theme briefs) were published on the IFPA website and translated into Spanish and Portuguese. Around 100 people attended the Forum in Bogota. Later in the year, two new resources (Roadmap for action and Action playbook) were published.

Preparations for the upcoming IFPA Forum Africa started. It will take place in Nairobi, Kenya, in May 7-9, 2026.

Science

'Share knowledge' is one of IFPA's strategic goals. By staying informed on the latest research and sharing knowledge IFPA contribute to closing the gap between knowledge and action, which is one of the challenges related to psoriatic disease. This is relevant for treatment and applies to IFPA's priority issues such as timely diagnosis, stigma, discrimination, equality and general understanding.

Reports and science-based aware-raising content

The connection between psoriatic disease and other non-communicable diseases is clear. Throughout the years several reports showcasing and explaining the link between psoriatic disease and its comorbidities have been created by IFPA. In 2025, we created a report highlighting the association between cardiovascular disease and psoriatic disease. This report was shared online, at scientific events, and members' meetings and with stakeholders.

To complement the in-depth reports that focused on each comorbidity, we also created a brochure with quick facts on the increased risk of developing comorbidities for people living with psoriatic disease. The brochure has been shared with our members, sponsors, at scientific conferences and advocacy events.

External science meetings

IFPA participated in Scientific dermatology and rheumatology conferences during the year. At some conferences we had a booth in the exhibition area. We contributed with lived experience, spoke up for patient centricity, family wellbeing, diversity, holistic care and much more.

AAD Annual Meeting, Orlando, March 7-11
The 2025 Annual Meeting of the American Academy of Dermatology took place in Orlando, Florida in March. More than 20,000 registrants showed up at the Orange County Convention Centre. IFPA held a sponsor meeting, where the delegation presented current plans for 2025. IFPA delegates and some members and ambassadors also participated in an advisory board and round table, sharing the patient perspective of living with psoriatic disease, in alignment with our goals. At the conference, the IFPA delegates attended the IPC symposium, sessions in relevant fields, and connected with key opinion leaders (KOLs).

EULAR, Barcelona, June 11-14
The European League Against Rheumatism (EULAR) Congress at Fira Barcelona Grand Via was attended by approximately 14,000 delegates. IFPA took the opportunity to showcase the work and resources we have developed on Psoriatic Arthritis (PsA) and interact with KOLs, EULAR patient engagement teams and other delegates. The IFPA delegation had fruitful meetings with sponsors and KOLs, and this year IFPA built important connections with the PARE group (People with Arthritis/Rheumatism in Europe). Some of these contacts have already resulted in successful connections with our members, and participation in joint events with other arthritis patient organizations. Following the annual meeting, IFPA has also become a EULAR Scientific Affiliate.

IDEOM, Washington DC, June 27-28
The IDEOM (International Dermatology Outcome Measures) annual meeting was held at the Hilton Washington DC National Mall The Wharf. This meeting was attended by physicians, patient research partners (PRPs), industry, medical students, caregivers, non-profit, and government, resident or fellows, researchers and patient administration. This is an extraordinary meeting where KOLs are invited to give input in outcome measures to be used in future clinical research.

APLAR, Fukuoka Japan, September 3-7
The Asian-Pacific League of Associations for Rheumatology congress at the Fukuoka International Convention Center was attended by over 2,500 attendees. IFPA had a booth at the congress. Many participants visited the booth, where we advertised the IFPA conference and content related to psoriatic arthritis.

ESDR, Antwerp, September 11-13
The European Societies of Dermatology Research happened at the Flanders Meeting & Convention Center and was attended by over 1,000 people. At the annual meeting, IFPA had

a booth where we showcased our documents, promoted the year theme #StopTheDominoEffect, shared dominoes and other content on the theme. The booth was located at the main area, where attendees mingled, had coffee and walked by to attend the different sessions. At this event, IFPA held a session in the main program, titled *"More Than Skin Deep: Addressing Psoriatic Disease and its comorbidities"*. More than 40 people attended and the positive feedback in the post-meeting survey included the presence of a patient representative sharing their story.

EADV, Paris, September 17-20

The European Academy of Dermatology and Venereology Congress (EADV) at the Paris Expo Porte de Versailles had over 20,000 delegates. IFPA attended sessions, co-hosted the joint patient booth provided by EADV, and organized a workshop entitled *"Talk That Heals: How Better Communication Drives Better Patient Outcomes"* which was also co-chaired by IFPA. Both before and at EADV, IFPA as member of the EADV Task Force actively collaborated to expand patient organization participation at the congress. IFPA held meetings with collaborators, other organizations, and met with potential new collaborators.

ACR, Chicago, October 24-29

American College of Rheumatology (ACR) Convergence took place at the McCormick Place in Chicago, Illinois. With 98 countries in attendance, 13,000 attendees, 155 exhibitors, 450 sessions and nearly 3,100 abstracts, the convergence represented the highest-impact research in the field of rheumatology. IFPA had a booth in the nonprofit area of the exhibition where we showcased the developed work and resources on Psoriatic Arthritis (PsA), advertised the IFPA Conference, and interacted with KOLs in rheumatology. IFPA presented "Lived Experience in Action: How Co-Creating a Psoriatic Arthritis Project Empowered My Journey as a Patient Advocate" in a session.

IFPA Conference

Established in 2006, the multidisciplinary IFPA Conference, also known as the World Psoriasis & Psoriatic Arthritis Conference, held every third year, provides a unique, cross-specialty platform. Medical and health professionals present frontline clinical research in dermatology, rheumatology and beyond. IFPA drives global scientific research through the IFPA Conference which has become a cornerstone event for medical and health professionals worldwide.

The IFPA Conference 2024 marked a significant milestone with the highest number of abstract submissions to date, reflecting groundbreaking research and advancements in the field. These abstracts are now published in Medicom Publishers and have been distributed in multiple congresses during 2025 providing valuable insights into the latest developments.

The next, 8th IFPA Conference (World Psoriasis & Psoriatic Arthritis Conference) will take place May 20-22, 2027, in Stockholm, Sweden.

Visit the conference website for more information: www.ifpaconference.com.

The Global Psoriasis Atlas (GPA)

The Global Psoriasis Atlas is an international project launched in 2016 by IFPA, International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC). It has made incredible progress and is delivered by global experts and an academic project team led by the University of Manchester. The vision is that the GPA will become the leading epidemiological resource globally on psoriasis providing the common benchmark on the burden of psoriasis in all countries and regions throughout the world. The Atlas will seek to: drive continuous improvement in understanding the natural history of psoriasis; uncover how it affects the individual and society; understand how healthcare can be improved for those living with the disease.

The GPA website is the first-ever comprehensive online epidemiological resource database tool. It contains data on the number of psoriasis cases, healthcare data and looks in depth at the experiences and faces behind people living with psoriasis.

In 2025, the Global Psoriasis Atlas launched its third edition on World Psoriasis Day, offering the most comprehensive look yet at psoriasis epidemiology worldwide. The new edition featured:

- Data from 58 new prevalence only studies
- Data from 4 new incidence only studies
- Coverage across 41 countries including 7 new ones
- Insights from 14 global regions
- New National Coordinators representing more than 40countries
- A revision of the heatmap updated on website front page visualizing the prevalence of psoriasis around the world.

IFPA developed Psoriasis Issue Briefs in collaboration with the GPA to support our member countries with data to systematically review and provide information on the incidence of psoriasis and to quantify global, regional, and country-specific estimates of its prevalence.

Example of studies by GPA published in 2025:

- Psoriasis and the risk of 26 cancers: pooled population-based cohort studies from Denmark, England, Israel, and Taiwan
- Skin disease in the Eastern Cape (SKINSCAPE): a Global Psoriasis Atlas point prevalence study in rural South Africa
- Grand Challenges for Skin Health Revisited: The International League of Dermatological Societies (ILDS) Skin Disease Atlases
- Epidemiology of Psoriasis in Poland: Prevalence, Incidence, and Mortality Rates

Further information is available on www.globalpsoriasisatlas.org.

Projects 2025

IFPA Ambassadors

IFPA continuously receive requests to contribute patient testimonials, survey participants, and stars for photo and video assets.

Through the Ambassador Training program IFPA have recruited a group of 23 ambassadors and given them training on advocacy messaging. Aims of the program are to unite a team of skilled ambassadors, reliable and ready to speak up for psoriatic disease and its comorbidities in the global arena. Their expert perspectives boost the diverse needs and experiences of people living with psoriatic disease, everywhere.

In 2025 the Ambassadors:

- Received training on storytelling and advocacy
- Presented their stories at conferences and on panels
- Directed personal initiatives to address psoriatic disease and comorbidities
- Collaborated for World Psoriasis Day
- Attended IFPA Forum
- Served on steering committees and participated in projects with civil society organizations and industry partners to raise awareness of patient priorities globally

Family Planning and Pregnancy

People living with psoriatic disease encounter specific challenges when planning a family, particularly young women who often lack adequate information and support. Limited time and awareness among healthcare professionals can contribute to these gaps, leaving individuals uncertain about treatment-related risks and how to ensure a safe pregnancy.

To better understand these needs, we conducted a global survey capturing the experiences of individuals with psoriatic disease and their partners. The insights guided the development of a practical checklist to support women of childbearing age in discussing birth control, pregnancy preparation, and navigating pregnancy and post-partum. The checklist was created in collaboration with members and ambassadors.

The findings and project outcomes will be presented at a scientific conference in 2026.

Economic burden of psoriatic disease comorbidities

In line with this year's theme, this project examined the economic impact of comorbidities in psoriatic disease for both individuals and healthcare systems. As effective systemic treatment can reduce comorbidity risk and long-term disease burden, the project assessed the potential financial benefits of such therapies.

Through a review of scientific literature, we identified comorbidity risks in moderate to severe psoriasis and psoriatic arthritis, associated healthcare costs, and developed a model estimating potential cost savings from different systemic treatments. The results indicate that, despite the higher upfront cost of advanced therapies, the reduction in comorbidity related expenses and overall burden makes these treatments economically favorable.

The work has been submitted to a peer reviewed scientific journal.

Psoriatic Arthritis Awareness

The IFPA GoodCare Project's successfully expanded outreach, improved accessibility, and strengthened partnerships to enhance Psoriatic Arthritis (PsA) awareness and support. Key achievements included disseminating educational materials at major events like EULAR, EADV and ACR. IFPA launched phase 3 of the project which has been running since 2022. Features of phase 3 include:

- Launching of the #1 Pocket Guide and illustration booklet
- Adding comorbidities and disease control in the global psoriatic arthritis arena

- Strengthening the role of ambassadors and members through the GoodCare fund
- Increasing participation in regional and global conferences, including the submission of poster presentations for conferences.

Materials available https://www.ifpa-pso.com/projects/psoriatic-arthritis-awareness.

Corporate Partners

In 2025, IFPA received funding from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, LEO Pharma, Novartis, Oruka, Pfizer, Takeda and UCB.

The support covered all from IFPA Partnership Program and Flagship programs to various projects and initiatives within science and advocacy to improve the lives of all people affected by psoriatic disease. Project sponsors are revealed under the project description on IFPA's website.

Administration report

The Board of IFPA hereby delivers the annual accounts for the full year of 2025. Regarding the result and financial positions, please refer to the following statements.

President
Ingvar Ágúst Ingvarsson
Reykjavik, Iceland

Vice President
Helen Crawford
Ottawa, Canada

Secretary
Sofia Lovi Ramasamy
Kuala Lumpur, Malaysia

Treasurer
Josef de Guzman
Manila, Philippines

Board Member
Silvia Fernandez Barrio
Buenos Aires, Argentina

Board Member
Masanori Okuse
Yokohama, Japan

Board Member
Jaime Melancia
Lisbon, Portugal

IFPA 2025
Org no 802428-5986

Income statement

		2025-01-01 2025-12-31		2024-01-01 2024-12-31	
	Note	SEK	EUR 10,818	SEK	EUR 11,4865
Operating income					
Membership fees		95 217	8 802	103 549	9 015
Contributions	**2**	16 865 460	1 559 018	18 571 402	1 616 803
Net revenue – IFPA Conference		0	0	1 456 070	126 764
Other operating income		22 341	2 065	12 737	1 109
Total operating income		**16 983 017**	**1 569 885**	**20 143 759**	**1 753 690**
Operating expenses					
Outgoing grants		-2 121 850	-196 141	-1 508 817	-131 356
Other operating expenses		-293 796	-27 158	-387 419	-33 728
Other external expenses	**3**	-10 541 404	-974 432	-10 819 469	-941 929
Staff & Project management		-9 147 331	-845 566	-7 390 086	-643 371
Total operating expenses		**-22 104 381**	**-2 043 296**	**-20 105 791**	**-1 750 384**
Operating result		**-5 121 363**	**-473 411**	**37 968**	**3 305**
Financial items					
Other interest income and similar items		544	50	241 365	21 013
Other interest expenses and similar items	**4**	-923 135	-85 333	-44 427	-3 868
Total financial items		**-922 591**	**-85 283**	**196 938**	**17 145**
Annual surplus (+) / deficit (-)		**-6 043 955**	**-558 694**	**234 906**	**20 451**

Costs per activity

	2025-01-01 2025-12-31		2024-01-01 2024-12-31	
20. Income	SEK	EUR 10,818	SEK	EUR 11, 4865
Other interest income and similar items	0	0	104 654	9 111
Other interest expenses and similar items	-17 270	-1 596	-2 214	-193
Total costs	**-17 270**	**-1 596**	**102 440**	**8 918**
30. Governance				
Other external expenses	-1 158 656	-107 104	-379 316	-33 023
Staff & Project management	-293 035	-27 088	-209 408	-18 231
Other interest expenses and similar items	-4 748	-439	-1 367	-119
Total costs	**-1 456 439**	**-134 631**	**-590 090**	**-51 373**
40. Members	SEK	EUR 10,818	SEK	EUR 11,4865
Outgoing grants	-524 377	-48 473	-236 790	-20 615
Other operating expenses	-57 041	-5 273	-81 100	-7 060
Other external expenses	-268 687	-24 837	-651 426	-56 712
Staff & Project management	-841 917	-77 826	-727 014	-63 293
Other interest income and similar items	64	6	608	53
Total costs	**-1 691 957**	**-156 402**	**-1 695 722**	**-147 627**
45. Accelerator				
Outgoing grants	-8 806	-814	-9 161	-798
Other operating expenses	-86 580	-8 003	-114 000	-9 925
Other external expenses	-87 356	-8 075	-175 239	-15 256
Staff & Project management	-276 910	-25 597	-192 170	-16 730
Other interest income and similar items	169	16	0	0
Other interest expenses and similar items	0	0	-884	-77
Total costs	**-459 482**	**-42 474**	**-491 453**	**-42 785**

Costs per activity

	2025-01-01 2025-12-31		2024-01-01 2024-12-31	
50. Secretariat and Staff	SEK	EUR 10,818	SEK	EUR 11,4865
Other external expenses	-1 304 675	-120 602	-639 305	-55 657
Staff & Project management	-2 234 028	-206 510	-1 190 919	-103 680
Other interest income and similar items	544	50	102 327	8 908
Other interest expenses and similar items	-843 685	-77 989	-41 588	-3 621
Total costs	**-4 381 845**	**-405 051**	**-1 769 485**	**-154 049**
60. Communication				
Other external expenses	-384 114	-35 507	-305 487	-26 595
Staff & Project management	-44 514	-4 115	-317 248	-27 619
Other interest income and similar items	0	0	647	56
Total costs	**-428 628**	**-39 622**	**-622 088**	**-54 158**
65. World Psoriasis Day	SEK	EUR 10,818	SEK	EUR 11,4865
Outgoing grants	0	0	-10 215	-889
Other external expenses	-387 024	-35 776	-286 332	-24 928
Staff & Project management	-527 331	-48 746	-583 302	-50 782
Other interest income and similar items	0	0	946	82
Other interest expenses and similar items	-1 518	-140	0	0
Total costs	**-915 873**	**-84 662**	**-878 903**	**-76 516**
70. Advocacy & Policy				
Other external expenses	-1 255 731	-116 078	-513 478	-44 703
Staff & Project management	-889 933	-82 264	-851 068	-74 093
Other interest expenses and similar items	-6 845	-633	-3 424	-298
Total costs	**-2 152 509**	**-198 975**	**-1 367 970**	**-119 094**

Costs per activity

	2025-01-01 2025-12-31		2024-01-01 2024-12-31	
71. IFPA Forum	SEK	EUR 10,818	SEK	EUR 11,4865
Outgoing grants	-324 540	-30 000	0	0
Other operating expenses	-150 175	-13 882	0	0
Other external expenses	-1 755 629	-162 288	-443 487	-38 609
Staff & Project management	-923 167	-85 336	0	0
Other interest income and similar items	1 383	128	2 131	185
Other interest expenses and similar items	-423	-39	0	0
Total costs	**-3 152 552**	**-291 417**	**-441 357**	**-38 424**
75. IFPA Coalition				
Other external expenses	-1 638 957	-151 503	-354 041	-30 822
Staff & Project management	-164 829	-15 237	-240 813	-20 965
Other interest expenses and similar items	0	0	-1	0
Total costs	**-1 803 786**	**-166 739**	**-594 855**	**-51 787**
80. Science	SEK	EUR 10,818	SEK	EUR 11,4865
Other external expenses	-1 544 348	-142 757	-971 654	-84 591
Staff & Project management	-1 383 269	-127 867	-1 367 821	-119 081
Other interest expenses and similar items	-768	-71	-1 886	-164
Total costs	**-2 928 385**	**-270 696**	**-2 341 361**	**-203 836**
85. IFPA Conference / WPPAC				
Other external expenses	786 918	72 742	-2 104 491	-183 214
Staff & Project management	-789 703	-72 999	0	0
Other interest income and similar items	2 785	257	342	30
Total costs	**0**	**0**	**-2 104 149**	**-183 185**

Costs per activity

	2025-01-01 2025-12-31		2024-01-01 2024-12-31	
90. Projects	SEK	EUR 10,818	SEK	EUR 11,4865
Outgoing grants	-1 264 128	-116 854	-1 252 651	-109 054
Other operating expenses	0	0	-192 319	-16 743
Other external expenses	-1 543 144	-142 646	-3 995 213	-347 818
Staff & Project management	-778 696	-71 981	-1 710 323	-148 898
Other interest income and similar items	0	0	36 955	3 217
Other interest expenses and similar items	-52 278	-4 833	-308	-27
Total costs	**-3 638 245**	**-336 314**	**-7 113 858**	**-619 323**

Balance sheet

		2025-01-01 2025-12-31		2024-01-01 2024-12-31	
Assets	**Note**	SEK	EUR 10,818	SEK	EUR 11,4865
Current assets					
Receivables					
Accounts receivables	**5**	553 776	51 190	1 593 825	138 756
Other receivables		120 496	11 138	319 118	27 782
Prepaid expenses and accrued income	**6**	1 698 594	157 016	284 061	24 730
Total receivables		**2 372 866**	**219 344**	**2 197 004**	**191 268**
Cash and bank balances					
Cash		1 376	127	1 444	126
Bank		4 873 806	450 527	15 102 352	1 314 791
Total cash and bank balances		**4 875 182**	**450 655**	**15 103 796**	**1 314 917**
Total assets		**7 248 048**	**669 999**	**17 300 799**	**1 506 185**

		2025-01-01 2025-12-31		2024-01-01 2024-12-31	
Equity and Liabilities	**Note**	SEK	EUR 10,818	SEK	EUR 11,4865
Equity					
Restricted funds	**7**	965 411	89 241	0	0
Retained earnings		8 365 095	773 257	9 095 600	791 851
Annual surplus/deficit		-6 043 955	-558 694	234 906	20 451
Total equity		**3 286 551**	**303 804**	**9 330 506**	**812 302**
Liabilities					
Current Liabilities					
Accounts payable		285 203	26 364	95 895	8 348
Other debts		880 031	81 349	843 320	73 418
Accrued expenses and deferred income	**8**	2 796 263	258 482	7 031 079	612 117
Total current liabilities		**3 961 496**	**366 195**	**7 970 293**	**693 884**
Total equity and liabilities		**7 248 048**	**669 999**	**17 300 799**	**1 506 185**

Notes

		2025-01-01 2025-12-31		2024-01-01 2024-12-31	
		SEK	EUR 10,818	SEK	EUR 11,4865

Note 1 Accounting principles
The annual accounts have been prepared in accordance with the Swedish simplified accounting standard for small entities (BFNAR 2017:3), also known as the K2 framework.

Note 2 Contributions

AbbVie		1 148 500	106 166	1 343 376	116 953
Almirall		1 663 794	153 799	1 569 887	136 672
Amgen		1 111 571	102 752	2 170 512	188 962
Boehringer Ingelheim		2 997 802	277 112	3 442 764	299 723
Bristol-Myers Squibb		1 106 000	102 237	1 560 044	135 815
Johnson & Johnson		1 520 298	140 534	385 882	33 594
LEO Pharma		1 263 505	116 797	1 065 093	92 726
Lilly		1 260 630	116 531	1 190 217	103 619
Novartis		361 355	33 403	626 812	54 569
Oruka		111 545	10 311	0	0
Pfizer		324 017	29 952	685 138	59 647
Takeda		1 838 976	169 992	1 280 488	111 478
UCB		2 157 468	199 433	3 251 190	283 044
Total		**16 865 460**	**1 559 018**	**18 571 402**	**1 616 803**

Notes

		2025-01-01 2025-12-31		2024-01-01 2024-12-31	
		SEK	EUR 10,818	SEK	EUR 11,4865

Note 3 Other external expenses

Office rental agreement		-731 909	-67 657	-493 990	-43 006
Software programs		-440 859	-40 752	-271 533	-23 639
Freight and transport		-2 211	-204	-604	-53
Conference costs		-1 549 373	-143 222	-1 060 733	-92 346
Travel costs		-1 815 965	-167 865	-1 170 055	-101 864
Refund members		-431 382	-39 876	-59 019	-5 138
Hotel costs		-886 414	-81 939	-628 468	-54 714
Food		-12 688	-1 173	-49 709	-4 328
Reimbursement		-142 129	-13 138	-177 285	-15 434
Printing costs		-433 595	-40 081	-189 937	-16 536
PR-Marketing		-966 355	-89 328	-1 148 235	-99 964
News service, PR		-299 067	-27 645	-349 877	-30 460
Hospitality		-3 515	-325	-8 770	-764
Gifts		0	0	-13 909	-1 211
Office material		-279 460	-25 833	-96 238	-8 378
Phone		-51 076	-4 721	-52 330	-4 556
Insurance for the organization		-22 098	-2 043	-20 345	-1 771
Losses on receivables		0	0	-663	-58
Honoraria for external		-70 207	-6 490	-96 992	-8 444
Accountant and audit		-75 715	-6 999	-73 045	-6 359
Consultants		-3 807 299	-351 941	-2 551 559	-222 135
Web		-140 775	-13 013	-158 951	-13 838
IT-costs		-106 051	-9 803	-69 281	-6 032
Membership fees		-256 749	-23 733	-296 946	-25 852
Other operating expenses		1 983 487	183 351	-1 780 995	-155 051
Total		**-10 541 404**	**-974 432**	**-10 819 469**	**-941 929**

Note 4 Other interest expenses and similar items

Interest taxes and fees		-2 691	-249	-3 358	-292
Bank fees		-43 972	-4 065	-41 069	-3 575
Exchange profit/loss		-876 472	-81 020	178 132	15 508
Total		**-923 135**	**-85 333**	**133 705**	**11 640**

Notes

		2025-01-01 2025-12-31		2024-01-01 2024-12-31	
		SEK	EUR 10,818	SEK	EUR 11,4865

Note 5 Accounts receivables

Takeda		523 505	48 392	57 917	5 042
Almirall		25 271	2 336	207 912	18 101
Boehringer Ingelheim		5 000	462	1 333	116
Lilly		0	0	1 318 188	114 760
UCB		0	0	8 475	738
Total		**553 776**	**51 190**	**1 593 825**	**138 756**

Note 6 Prepaid expenses and accrued income

Prepaid expenses

IFPA Conference 2027		1 350 010	124 793	0	0
Helioworks Slottsbacken		280 500	25 929	116 455	10 138
Hubspot		16 239	1 501	0	0
AIG Europe		15 725	1 454	12 598	1 097
Prepaid membership fee GHC 2026		9 292	859	10 960	954
Reimbursement		8 744	808	0	0
Lisa Technologies		7 818	723	8 120	707
Learnifier		4 313	399	4 313	375
Fortnox		3 193	295	2 490	217
Söderberg & Partners Insurance Consulting		1 719	159	1 456	127
Loopia		1 043	96	893	78
StellarUp		0	0	50 655	4 410
Scrive		0	0	2 681	233
		1 698 594	*157 016*	*210 620*	*18 336*

Accrued income

Nordea Bank Abp		0	0	62 820	5 469
NH Collection Hotel Rome		0	0	8 941	778
Camp Ripan		0	0	1 680	146
		0	*0*	*73 440*	*6 394*
Total		**1 698 594**	**157 016**	**284 061**	**24 730**

Note 7 Restricted funds

Ambassador program		965 411	89 241	0	0
Total		**965 411**	**89 241**	**0**	**0**

Notes

		2025-01-01 2025-12-31		2024-01-01 2024-12-31	
		SEK	EUR 10,818	SEK	EUR 11,4865
Note 8 Accrued expenses and deferred income					
Accrued expenses					
IFPA Funds		711 824	65 800	0	0
Accrued vacation pay liability		628 221	58 072	483 062	42 055
Accrued cost IFPA Projects		336 340	31 091	980 031	85 320
Hummelkläppen		50 000	4 622	52 500	4 571
Collectum		40 171	3 713	30 837	2 685
Firstcard		22 726	2 101	15 040	1 309
Travel reimbursements IFPA Board		5 401	499	5 083	443
Tele2		3 772	349	3 096	270
Grant Thornton		0	0	93 750	8 162
AEPSO, Argentina		0	0	10 442	909
Nordea Bank Abp		0	0	2 949	257
Helioworks Slottsbacken		0	0	2 703	235
Republic Factory		0	0	1 500	131
Staff outlays		0	0	1 000	87
Fortnox		0	0	409	36
		1 798 455	*166 247*	*1 682 402*	*146 468*
Deferred income					
Accounts receivables					
Takeda		666 052	61 569	262 845	22 883
UCB		320 547	29 631	1 320 660	114 975
Johnson & Johnsson		0	0	1 333 080	116 056
Lilly		0	0	1 318 188	114 760
Amgen		0	0	1 111 571	96 772
		986 599	*91 200*	*5 346 343*	*465 446*
Membership fees					
Indonesia 2026-2029		4 033	373	0	0
Israel 2026		2 911	269	0	0
Singapore 2026-2027		1 995	184	0	0
Australia 2026-2029		1 069	99	0	0
Russia 2026-2027		992	92	568	49
Uruguay 2026		207	19	413	36
Vietnam 2025		0	0	574	50
Argentina 2025		0	0	531	46
Kenya 2025		0	0	247	22
		11 208	*1 036*	*2 333*	*203*
Total		**2 796 263**	**258 482**	**7 031 079**	**612 117**

Signatures

Approved at the IFPA Board Meeting on April 7, 2026.
Each electronic signature indicates its respective signing date.

Ingvar Ágúst Ingvarsson
President

Helen Crawford
Vice President

Sofia Lovi Ramasamy
Secretary

Josefino de Guzman
Treasurer

Silvia Fernandez Barrio
Board Member

Masanori Okuse
Board Member

Jaime Melancia
Board Member

My auditor's report has been issued on the date indicated in my electronic signature.

Hummelkläppen i Stockholm AB

Tommy Nilsson
Authorized Public Accountant

IFPA

GLOBAL LEADER IN FIGHTING PSORIATIC DISEASE

Slottsbacken 8
111 30 Stockholm, SWEDEN

ifpa-pso.com

info@ifpa-pso.com

@psoriasisIFPA